IM-1240

N/A

Report date: 2026/03/19 17:15:58

Base Information

Drug NameIM-1240

Drug Alias NameIM1240IM-1240CAPTN-3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionNatural killer cells stimulantsT lymphocytes stimulantsAnti-Trophoblast glycoprotein +[5]

TargetsTrophoblast glycoproteinT cell surface glycoprotein CD3NK cell lectin-like receptor subfamily C member 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPurple Biotech Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPurple Biotech Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A